VTGN - Vistagen posts real world data to highlight hot flashes therapy
2023-06-07 09:46:39 ET
Vistagen ( NASDAQ: VTGN ) announced Wednesday that its nasal spray therapy PH80 led to a statistically significant efficacy compared to placebo in a mid-stage real-world study as an acute therapy for hot flashes.
Citing data from an exploratory Phase 2A study conducted by its subsidiary Pherin Pharmaceuticals in Mexico, Vistagen said that after four weeks of therapy, those on PH80 recorded 1.5 hot flashes compared to 5.1 events in the placebo group.
At the baseline, the two groups reported a mean daily number of 7.7 (PH80, n=18) and 8.0 (placebo, n=18) hot flashes. All 36 subjects completed the study, and the experimental therapy was well tolerated with no serious adverse events.
Women in menopause experience hot flashes, also known as vasomotor symptoms, characterized by signs such as night sweats and flushed skin.
More on VistaGen
- VistaGen acquiring Pherin Pharma acquisition to bolster neuropsychiatric portfolio
- Vistagen up 17% after Phase 3 data for anxiety candidate
For further details see:
Vistagen posts real world data to highlight hot flashes therapy